Business Context and Reporting Period
This Form 8-K is a current report filed by Cerulean Pharma Inc. on May 27, 2014. The filing serves as a Regulation FD disclosure to announce operational highlights for the quarter ended March 31, 2014, and anticipated corporate milestones for the remainder of 2014. Note: The input metadata references "Dare Bioscience, Inc.," but the filing text explicitly identifies the registrant as Cerulean Pharma Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a press release (Exhibit 99.1) containing these details, but the text of the press release is not included in the provided input.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It only indicates that operational highlights for the quarter ended March 31, 2014, were announced in the attached press release.
Guidance, Outlook, and Risks
Management announced anticipated corporate milestones for the remainder of 2014. The filing explicitly states that the information contained in the press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Verify the specific operational highlights and financial results for the quarter ended March 31, 2014, by reviewing the attached press release (Exhibit 99.1).
- Confirm the details of the anticipated corporate milestones for the remainder of 2014.
- Review the full text of the press release to obtain missing financial metrics such as cash position and burn rate, as they are not present in the 8-K summary text.
- Note the legal disclaimer regarding the non-filing status of the press release information under Section 18 of the Exchange Act.